Nautilus Biotechnology Reports Q3 2026 Net Loss of $15.6M
The company reported Q3 2026 revenue of $0.2M, operating expenses of $16.9M and cash, cash equivalents and investments of $114.3M as of Sept. 30, 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.